Patents Assigned to Cetus Oncology Corporation
  • Patent number: 6238891
    Abstract: A method of determining the optimal level of product expression and cell growth of animal cell culture is described. The method generally comprises culturing cells under conditions of solute stress, that is, under conditions whereby optimal cell growth or growth rate is decreased yet levels of product expression are increased. In a preferred embodiment of the invention is described a method of increasing the yield of monoclonal antibodies comprising culturing hybridoma cells in an environment of solute stress. One approach to the creation of such an environment is the addition of inorganic salts, organic polyols, or metabolic products to the culture medium. One- to three-fold increases in antibody yield have been obtained by these methods.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 29, 2001
    Assignee: Cetus Oncology Corporation
    Inventors: Brian Maiorella, Duane Inlow, William Howarth
  • Patent number: 5639593
    Abstract: Compositions and methods are described for identifying inhibitors of mature protein hormone formation from a prohormone, and prophylactic and therapeutic uses of the inhibitors for treating diseases associated with elevated levels of the mature hormones, particulary sepsis, AIDS and autoimmune diseases.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: June 17, 1997
    Assignee: Cetus Oncology Corporation
    Inventors: Michael Kriegler, Danute E. Nitecki
  • Patent number: 5629197
    Abstract: Murine monoclonal antibodies are prepared and characterized which bind selectively to high molecular weight mucins by immunoprecipitation test and are IgGs or IgMs. Immunotoxins comprising the monoclonal antibody and cytotoxic moiety were produced.
    Type: Grant
    Filed: August 11, 1994
    Date of Patent: May 13, 1997
    Assignee: Cetus Oncology Corporation
    Inventors: David B. Ring, Arthur E. Frankel, Michael J. Bjorn
  • Patent number: 5591827
    Abstract: This invention provides a class of interleukin-6 (IL-6) muteins which act as IL-6 receptor antagonists, thereby inhibiting the normal function of naturally-occurring IL-6. These IL-6 receptor antagonists are preferably IL-6 molecules containing one or more mutations in the Site II region comprising amino acids 154-163. This invention also provides pharmaceutical compositions comprising IL-6 receptor antagonists with a pharmaceutically acceptable carrier. This invention further provides methods for treating IL-6 related diseases such as sepsis and multiple myeloma, the methods comprising administering to a patient an IL-6 receptor antagonist.
    Type: Grant
    Filed: December 16, 1994
    Date of Patent: January 7, 1997
    Assignee: Cetus Oncology Corporation
    Inventors: Just P. J. Brakenhoff, Lucien A. Aarden
  • Patent number: 5573930
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.
    Type: Grant
    Filed: December 28, 1992
    Date of Patent: November 12, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Y. Coyne, Robert F. Halenbeck, Kirston E. Koths
  • Patent number: 5556620
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: March 31, 1994
    Date of Patent: September 17, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Peter Ralph, Sharon Auckerman, James Devlin
  • Patent number: 5545518
    Abstract: Compositions and methods are described for identifying inhibitors of mature protein hormone formation from a prohormone, and prophylactic and therapeutic uses of the inhibitors for treating diseases associated with elevated levels of the mature hormones, particulary sepsis, and autoimmune diseases.
    Type: Grant
    Filed: February 8, 1995
    Date of Patent: August 13, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Michael Kriegler, Danute E. Nitecki
  • Patent number: 5538868
    Abstract: Recombinant vectors and methods for constructing ricin B are disclosed. The coding sequence for ricin B was cloned, disposed in suitable expression vectors and produced free of components normally accompanying this peptide. In addition, a novel means of reconstructing missing portions of coding sequence, and certain improvements in messenger RNA purification are disclosed.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: July 23, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Glenn T. Horn, Michael Piatak, Jr.
  • Patent number: 5508031
    Abstract: Damage to cells, tissue and other body parts in a mammalian host may be treated by using a lymphokine or cytotoxin in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a combination may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.
    Type: Grant
    Filed: August 12, 1994
    Date of Patent: April 16, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Robert Zimmerman, Benedict J. Marafino, Jr.
  • Patent number: 5503841
    Abstract: Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.
    Type: Grant
    Filed: February 24, 1989
    Date of Patent: April 2, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Michael V. Doyle, Arthur D. Newell, Jack H. Nunberg, Thomas J. White
  • Patent number: 5491065
    Abstract: Monoclonal antibodies that bind to an apparent conformational epitope associated with recombinant or native dimeric M-CSF with concomitant neutralization of biological activity, which monoclonal antibodies are substantially unreactive with biologically inactive forms of M-CSF including monomeric and chemically derivatized dimeric M-CSF, are described. Methods of using the antibodies in assays for detection of dimeric M-CSF are also described.
    Type: Grant
    Filed: November 19, 1993
    Date of Patent: February 13, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Robert F. Halenbeck, Kirston E. Koths, Joseph W. Wrin
  • Patent number: 5470569
    Abstract: A colony stimulating factor. CSF-1, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: November 28, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: Ernest S. Kawasaki, Martha B. Ladner, Janelle N. Van Arsdell, Alice M. Wang, Peter Ralph, Mazie Y. Coyne, Mary K. Warren
  • Patent number: 5464936
    Abstract: Medicaments, and methods of identifying the same, are described that are useful for treating papillomavirus diseases that have the characteristics of preventing, interfering with, or reversing the binding of the appropriate papillomavirus proteins E1 or E2 to a nucleotide sequence homologous to a nucleotide sequence present in the papillomavirus genome, or of the formation of a complex consisting of papillomavirus proteins E1 and E2, or the binding of the complex to the nucleotide sequence.
    Type: Grant
    Filed: December 21, 1990
    Date of Patent: November 7, 1995
    Assignees: Cetus Oncology Corporation, University of California
    Inventors: Michael R. Botchan, Robin Clark, Ian J. Mohr, Shaw Sun
  • Patent number: 5455330
    Abstract: Medicaments that have prophylactic or therapeutic applications for the treatment of disease resulting from the production of cytokines, particularly IL-1, that effectively inhibit the biological activity of the cytokines wherein the medicaments are characterized by being proteinaceous materials lacking a signal sequence for which a cDNA sequence has been identified and sequenced.
    Type: Grant
    Filed: June 30, 1993
    Date of Patent: October 3, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: John S. Haskill, George Martin, Peter Ralph
  • Patent number: 5425940
    Abstract: Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-.beta., or of TNF, IL-2 and IFN-.beta. in combination. The composition of TNF and IL-2 and/or IFN-.beta. may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, lymphoma, mammary adenocarcinoma, and pharyngeal squamous cell carcinoma.
    Type: Grant
    Filed: February 3, 1994
    Date of Patent: June 20, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: Robert Zimmerman, Jeffrey L. Winkelhake
  • Patent number: 5422105
    Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, vital or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.
    Type: Grant
    Filed: March 1, 1994
    Date of Patent: June 6, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: Peter Ralph, Kong T. Chong
  • Patent number: 5422425
    Abstract: Compositions and methods are described for identifying inhibitors of mature protein hormone formation from a prohormone, and prophylactic and therapeutic uses of the inhibitors for treating diseases associated with elevated levels of the mature hormones, particulary sepsis, and autoimmune diseases.
    Type: Grant
    Filed: April 26, 1993
    Date of Patent: June 6, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: Michael Kriegler, Danute E. Nitecki
  • Patent number: 5397703
    Abstract: The present invention relates to a method of generating antibodies directed against cell surface antigens. The method uses as immunogen recombinant insect cells into which have been transfected coding regions for a molecule containing a cell surface antigen. Host animals are immunized with these transfected insect cells to generate antibodies directed against the cell surface antigen. Antibody-producing cells from the host animal are used to generate monoclonal antibody-producing hybridoma cells. Sera and hybridoma supernatants can be tested for the presence of antibodies against the surface antigen, using the transfected cells in a screening assay.
    Type: Grant
    Filed: July 9, 1992
    Date of Patent: March 14, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: Mark De Boer, Leah B. Conroy
  • Patent number: 5324655
    Abstract: A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF. Particularly disclosed is a DNA construct in which a gene encoding tumor necrosis factor (TNF) is directly linked to DNA encoding a human .gamma.-interferon signal peptide.
    Type: Grant
    Filed: February 18, 1992
    Date of Patent: June 28, 1994
    Assignee: Cetus Oncology Corporation
    Inventors: Michael Kriegler, Carl Perez
  • Patent number: RE35171
    Abstract: Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whereby the compositions are used to identify cancer therapeutics.
    Type: Grant
    Filed: April 14, 1994
    Date of Patent: March 5, 1996
    Assignee: Cetus Oncology Corporation
    Inventors: Francis P. McCormick, Kirston E. Koths, Robert F. Halenbeck, Mary M. Trahey